Indivior (LON:INDV) said today that the FDA’s psychopharmacologic drugs advisory committee and drug safety and risk management advisory committee voted 18-1 recommending approval of the company’s once-monthly injectable treatment for opioid use disorder.
The company’s RBP-6000 treatment is designed for adults with moderate-to-severe opioid use disorder. The FDA is slated to make a decision about Indivior’s product by the end of November.
Get the full story at our sister site, Drug Delivery Business News.